Loading clinical trials...
Loading clinical trials...
Clinical Study to Evaluate the Safety and Tolerability of Immunoglobulin Intravenous (Human) 10% (NewGam) Administered at High Infusion Rates to Patients With Primary Immunodeficiency Diseases (Extension of Study NGAM-01)
Conditions
Interventions
NewGam
Locations
6
United States
University of California Irvine
Irvine, California, United States
Immunoe Research Center
Centennial, Colorado, United States
Rush Universtity Medical Center
Chicago, Illinois, United States
Cardinal Glennon Children's Hospital
St Louis, Missouri, United States
Midlands Pediatrics
Papillion, Nebraska, United States
Seattle Children's Hospital
Seattle, Washington, United States
Start Date
May 1, 2011
Primary Completion Date
September 1, 2012
Completion Date
September 1, 2012
Last Updated
March 29, 2017
NCT07346859
NCT04944979
NCT05236764
NCT05755035
NCT05513586
NCT06955793
Lead Sponsor
Octapharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions